Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
Holding IRWD?
Track your performance easily
Earnings Data
Report Date
Feb 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.06Last Year’s EPS
-$0.01Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -11.71%
|Next Earnings Date:Feb 13, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted robust prescription growth for LINZESS and significant progress with apraglutide, indicating a strong market position and potential for future growth. However, considerable pricing pressures on LINZESS and program adjustments in the pipeline present notable challenges.Company Guidance
During the Ironwood Pharmaceuticals Q3 2024 earnings call, the company provided several key metrics and guidance for the upcoming periods. LINZESS U.S. net sales were reported at $226 million for the third quarter, with a year-over-year prescription demand growth of 13%. Despite this growth, LINZESS faced pricing headwinds, largely due to an increase in Medicaid prescriptions. Ironwood maintained its full-year 2024 guidance, projecting LINZESS U.S. net sales between $900 million and $950 million, Ironwood revenue of $350 million to $375 million, and adjusted EBITDA greater than $75 million. The company generated $10 million in operating cash flow and $26 million in adjusted EBITDA for the quarter. Looking ahead, Ironwood aims to manage LINZESS pricing pressures while advancing apraglutide towards an NDA submission in Q1 2025, targeting a commercial launch in 2026.LINZESS Prescription Growth
LINZESS experienced a 13% year-over-year increase in prescription demand and new-to-brand prescriptions in Q3 2024, marking the seventh consecutive quarter of double-digit growth.
Apraglutide Progress
The company remains on track to submit an NDA for apraglutide in Q1 2025. Phase III data has shown positive results, and the drug has received recognition, including the ACG's Presidential Poster Award.
Strong Financial Position
The company generated $10 million in operating cash flow and $26 million in adjusted EBITDA in Q3 2024. They also repaid $25 million of debt, strengthening their balance sheet.
---
IRWD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IRWD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $5.04 | $4.66 | -7.54% |
| Aug 08, 2024 | $6.01 | $4.05 | -32.61% |
| May 09, 2024 | $8.12 | $6.74 | -17.00% |
| Feb 15, 2024 | $15.45 | $14.99 | -2.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ironwood Pharma (IRWD) report earnings?
Ironwood Pharma (IRWD) is schdueled to report earning on Feb 13, 2025, TBA Not Confirmed.
What is Ironwood Pharma (IRWD) earnings time?
Ironwood Pharma (IRWD) earnings time is at Feb 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IRWD EPS forecast?
IRWD EPS forecast for the fiscal quarter 2024 (Q4) is $0.06.
---